Benefits
Body fat + visceral fat 8-week dose-finding RCT (Tominaga 2009 PIVOTAL)
Tominaga 2009 (J Health Sci/J Funct Foods) — 8-week randomized double-blind placebo-controlled dose-finding trial in 84 overweight adults (56 men, 28 women aged 40-60, BMI 24-30 kg/m²). Four groups: placebo, 300 mg, 600 mg, or 900 mg Kaneka Glavonoid™ LFO/day. RESULTS: 300 mg dose lost 0.92 kg body fat (vs placebo); 900 mg dose lost 0.89 kg body fat. 900 mg dose: 9.35 cm³ REDUCTION in VISCERAL FAT AREA + 0.25 kg/m² DECREASE IN BMI + 11 mg/dL REDUCTION in LDL-CHOLESTEROL. Body composition measured by DXA + abdominal CT scan. Foundational pivotal dose-finding trial.
12-week body weight loss in overweight (Tominaga 2006)
Tominaga 2006 — 12-week trial at 300 mg LFO/day showed SIGNIFICANT REDUCTIONS in BODY MASS attributed to BODY FAT MASS in overweight subjects vs placebo. Foundational positive long-duration RCT supporting weight management claims at lower dose (300 mg/day). Demonstrates effects sustained beyond 8 weeks.
US visceral fat trial (Tominaga 2014 Nutrafoods)
Tominaga Y, Kitano M, Mae T, Kakimoto S, Nakagawa K 2014 (Nutrafoods 13:35-43) — Effect of licorice flavonoid oil on visceral fat in OBESE subjects in the United States. Randomized double-blind placebo-controlled study. CONFIRMS Tominaga 2009 visceral fat findings in US population. Important geographic generalizability evidence.
Elderly muscle mass increase (Kinoshita 2017)
Kinoshita 2017 (J Sci Food Agric) — randomized double-blind placebo-controlled trial. Effects of LFO on INCREASING MUSCLE MASS of elderly populations. 300 mg/day LFO for 8 weeks. RESULTS: muscle mass INCREASE in elderly. Important sarcopenia-prevention application — common challenge in older adults. Mechanism: visceral fat reduction + muscle preservation effects of glabridin.
LDL-cholesterol reduction 11 mg/dL (Tominaga 2009)
Tominaga 2009 dose-dependent LDL-cholesterol reduction: 11 mg/dL LDL-C reduction at 900 mg/day dose. Mechanism: lipogenesis inhibition + lipid metabolism modulation. Cardiovascular risk reduction beyond pure body composition changes.
ATTR amyloid prevention (12-week Glavonoid)
Oral Glavonoid 300 mg for 12 weeks in 7 healthy volunteers EFFECTIVELY INCREASED PLASMA GLABRIDIN concentration. Glavonoid INCREASED TTR (transthyretin) TETRAMER LEVEL and REDUCED MONOMER/TETRAMER RATIO of TTR (P<0.05) at 12 weeks vs age-matched controls. Mechanism: TTR tetramer stabilization may PREVENT TTR amyloid fibril formation. Promising preventive application before onset of ATTR (transthyretin amyloidosis). Novel evidence for rare disease prevention.
Beta-oxidation enhancement + lipogenesis inhibition (mechanism)
Mechanism: licorice flavonoid oil INCREASES ENERGY EXPENDITURE by ENHANCING BETA-OXIDATION + INHIBITS LIPOGENESIS resulting in body fat reduction. GRO-supplementation reduces stearoyl-coenzyme A desaturase 1 (SCD1) expression — key adipogenesis enzyme. Mechanism distinct from many other weight management supplements.
Mechanism of action
Beta-oxidation enhancement (energy expenditure increase)
Licorice flavonoid oil INCREASES ENERGY EXPENDITURE by ENHANCING BETA-OXIDATION (fatty acid metabolism). Mechanism for fat-burning effects beyond appetite suppression. Distinguishes from many weight management supplements relying on appetite mechanisms.
Lipogenesis inhibition
INHIBITS LIPOGENESIS (new fat synthesis) at adipocyte level. Mechanism: SCD1 (stearoyl-coenzyme A desaturase 1) expression reduction — key enzyme in adipogenesis. Combined with beta-oxidation enhancement provides dual mechanism for body fat reduction.
Glabridin (3% standardized) bioactive
Glabridin is the major flavonoid bioactive — DISTINCT from glycyrrhizin (which causes pseudoaldosteronism in crude licorice). Glabridin shows: anti-obesity, anti-inflammatory, antioxidant, anti-melanogenesis (skin lightening), neuroprotective effects. Multi-target mechanism via single compound.
MCT oil delivery (bioavailability)
Licorice flavonoid oil dissolved in MEDIUM-CHAIN TRIGLYCERIDES (MCT, C8:C10 = 99:1). Mechanism: MCT enhances absorption of lipophilic flavonoids via direct portal vein delivery + thermogenic effects of MCT itself. Delivery system distinguishes Glavonoid from typical licorice extracts.
TTR (transthyretin) tetramer stabilization
Stabilizes TTR tetramer + reduces monomer/tetramer ratio in plasma (12-week trial). Mechanism for ATTR amyloid prevention. Distinct from weight management mechanisms — important emerging application.
NO glycyrrhizin (safety mechanism)
Critical distinguishing feature: Glavonoid® is FLAVONOID FRACTION, NOT glycyrrhizin fraction. NO pseudoaldosteronism risk at recommended doses (vs crude licorice which causes hypokalemia, hypertension, edema with chronic use). Safety advantage allowing chronic use that crude licorice cannot.
Anti-inflammatory effects
Glabridin and other licorice flavonoids suppress NF-κB and pro-inflammatory cytokines. Mechanism for anti-inflammatory benefits in metabolic syndrome context.
Clinical trials
8-week randomized double-blind placebo-controlled dose-finding study (Tominaga Y, Nakagawa K, Mae T, Kitano M, Yokota S, Arai T, Ikematsu H, Inoue S 2009).
84 moderately overweight adults (56 males, 28 females, BMI 24-30 kg/m², aged 40-60). Four arms: placebo, 300 mg, 600 mg, or 900 mg Kaneka Glavonoid™ LFO/day. Total body fat by DXA + visceral fat by abdominal CT scan + body weight + BMI + blood samples at baseline and 8 weeks.
300 mg dose: 0.92 kg body fat reduction vs placebo. 900 mg dose: 0.89 kg body fat reduction + 9.35 cm³ VISCERAL FAT AREA REDUCTION + 0.25 kg/m² BMI DECREASE + 11 mg/dL LDL-CHOLESTEROL REDUCTION. Energy intake similar across groups — effects via metabolic mechanism not caloric reduction. Foundational pivotal dose-finding RCT establishing 300-900 mg/day effective dose range. INDUSTRY-SPONSORED (Kaneka Corporation) — important context.
Randomized double-blind placebo-controlled trial (Kinoshita 2017, J Sci Food Agric, doi:10.1002/jsfa.8044).
Elderly populations. LFO 300 mg/day for 8 weeks vs placebo. Muscle mass + body composition assessed.
LFO 300 mg/day INCREASED MUSCLE MASS in elderly populations. Important sarcopenia-prevention application. Mechanism: visceral fat reduction + muscle preservation effects via glabridin. Demonstrates dual body composition benefit (visceral fat reduction + muscle increase) vs typical weight management supplements that may decrease muscle.
Randomized double-blind placebo-controlled study (Tominaga Y, Kitano M, Mae T, Kakimoto S, Nakagawa K 2014, Nutrafoods 13:35-43).
Obese subjects in the United States. Effect of licorice flavonoid oil on visceral fat.
CONFIRMS Tominaga 2009 visceral fat findings in US OBESE POPULATION. Important geographic generalizability evidence — Japanese vs US populations may have different responses. Replicated visceral fat reduction supports broader applicability.
About this ingredient
Kaneka Glavonoid™ / Glavonoid® is a BRANDED LICORICE FLAVONOID OIL (LFO) manufactured by KANEKA CORPORATION (Japan). Composition: 30% LICORICE ETHANOLIC EXTRACT dissolved in MEDIUM-CHAIN TRIGLYCERIDES (MCT, C8:C10 fatty acids = 99:1). STANDARDIZED to 3% GLABRIDIN (major flavonoid bioactive). Additional flavonoids: glabrol, licoricidin, hispaglabridin.
CRITICAL DISTINGUISHING FEATURE: GLAVONOID IS THE FLAVONOID FRACTION OF LICORICE, NOT THE GLYCYRRHIZIN FRACTION. Crude licorice contains glycyrrhizin which causes PSEUDOALDOSTERONISM (hypokalemia, hypertension, edema, heart problems with chronic use) — this is why crude licorice has FDA warnings for chronic use. Glavonoid® EXCLUDES glycyrrhizin allowing chronic safe use. PIVOTAL CLINICAL EVIDENCE: TOMINAGA 2009 (J Health Sci/J Funct Foods) — 8-week dose-finding RCT in 84 overweight adults BMI 24-30 at 300/600/900 mg/day showing dose-dependent body fat reductions, 9.35 cm³ visceral fat area reduction, 0.25 kg/m² BMI decrease, 11 mg/dL LDL-C reduction at highest dose. KINOSHITA 2017 (J Sci Food Agric) — elderly muscle mass increase trial at 300 mg/day. TOMINAGA 2014 (Nutrafoods 13:35-43) — US visceral fat trial confirming Japanese findings. TOMINAGA 2006 — 12-week body weight loss trial at 300 mg/day. ATTR AMYLOID PREVENTION TRIAL — 12-week 300 mg Glavonoid in 7 healthy volunteers stabilized TTR tetramer + reduced monomer/tetramer ratio (P<0.05) — promising before-onset prevention application. Multiple Japanese and Western RCTs support claims. Total of 26 clinical trials in 985 patients per quantitative synthesis.
MECHANISMS: Beta-oxidation enhancement (energy expenditure increase via enhanced fatty acid metabolism); Lipogenesis inhibition (SCD1 stearoyl-coenzyme A desaturase 1 expression reduction at adipocyte level); Glabridin multi-target bioactive (anti-obesity, anti-inflammatory, antioxidant, neuroprotective, anti-melanogenesis); MCT oil delivery enhancement; TTR tetramer stabilization (ATTR amyloid prevention); NF-κB anti-inflammatory pathway suppression. NO GLYCYRRHIZIN — critical safety mechanism allowing chronic use. EVIDENCE: 3/5 reflects: (1) TOMINAGA 2009 PIVOTAL DOSE-FINDING RCT with statistically significant dose-dependent body fat + visceral fat + BMI + LDL-C reductions, (2) TOMINAGA 2014 US population replication, (3) KINOSHITA 2017 elderly muscle mass evidence (sarcopenia prevention), (4) TOMINAGA 2006 12-week sustained weight loss evidence, (5) WELL-CHARACTERIZED beta-oxidation + lipogenesis inhibition mechanisms, (6) ATTR amyloid TTR tetramer stabilization emerging evidence, (7) 26 clinical trials in 985 patients per quantitative synthesis, (8) GLYCYRRHIZIN-FREE distinguishing safety profile vs crude licorice, (9) industry-sponsored evidence (Kaneka) — important context but methodology rigorous, (10) higher-evidence than typical 'licorice supplement' due to flavonoid fraction + standardization + dose-finding RCT. SAFETY: Excellent — flavonoid fraction (no glycyrrhizin) + clinical trial safety record. Best positioned as: (a) WEIGHT MANAGEMENT in overweight adults BMI 24-30 (Tominaga 2009 PIVOTAL evidence), (b) VISCERAL FAT reduction adjunct (~9 cm³ area reduction at 900 mg/day), (c) ELDERLY MUSCLE PRESERVATION + visceral fat reduction (Kinoshita 2017 sarcopenia prevention), (d) METABOLIC SYNDROME adjunct (LDL-C reduction + body composition), (e) DAILY long-term use acceptable based on glycyrrhizin-free safety profile (vs crude licorice limited to ≤6 weeks chronic use), (f) ATTR amyloidosis PREVENTION before onset (emerging application), (g) GLYCYRRHIZIN-FREE alternative to crude licorice for those wanting flavonoid benefits without pseudoaldosteronism risk, (h) PREGNANCY: AVOID, (i) industry-sponsored evidence — important context but methodology rigorous. Honest framing: Glavonoid® has more rigorous evidence than typical licorice supplements — Tominaga 2009 PIVOTAL dose-finding RCT with statistically significant body fat + visceral fat + BMI + LDL-C reductions is methodologically robust. The glycyrrhizin-free flavonoid fraction is a genuine pharmacological + safety distinction. Kinoshita 2017 elderly muscle mass increase + visceral fat reduction dual benefit is genuinely unusual among weight management supplements. ATTR amyloid prevention via TTR stabilization is emerging novel application. Kaneka Corporation industry sponsorship warrants caveat but methodology consistently rigorous. Reasonable weight management + metabolic syndrome adjunct based on evidence — particularly compelling for overweight adults wanting visceral fat targeting + cholesterol benefits without crude-licorice safety concerns.